Biotest AG
- ISIN DE0005227235
- Country Deutschland
Company profile
Biotest is a specialist in innovative haematology, clinical immunology and intensive care medicine. Biotest develops, manufactures and markets plasma proteins and biotherapeutic drugs. Our value chain extends from pre-clinical and clinical development to worldwide marketing and distribution. Biotest manufactures immunoglobulins, clotting factors and albumins which derive from human blood plasma. Biotest currently employs more than 2,400 people worldwide.
The most important raw material for our pharmaceuticals is human blood plasma, which we process into effective and highly purified drugs in one of our world leading fractionation facilities in Europe. These medications are used to treat life-threatening diseases such as blood coagulation disorders (haemophilia), severe infections and immune system disorders.
The most important raw material for our pharmaceuticals is human blood plasma, which we process into effective and highly purified drugs in one of our world leading fractionation facilities in Europe. These medications are used to treat life-threatening diseases such as blood coagulation disorders (haemophilia), severe infections and immune system disorders.
Management
Peter Janssen
Chairman of the Board of Management
Peter Janssen is CEO and Chairman of the Management Board since January, 2024 – he has been member of the Management Board since 2022. He was previously leading Commercial and Industrial Operations as COO. Before joining Biotest, he was Executive VP of Prothya Netherlands and CEO of Prothya Belgium. Mr. Janssen also worked 14 years for Pfizer and 5 years for its animal health spin-off Zoetis where he performed various transformational, strategic and global operational roles with increasing responsibilities.
Peter started his career as an assistant Professor at the University of Leuven in Belgium, was a reserve officer at the Belgian Air Force and worked in the semiconductor division of Air Products in Pennsylvania, US. He holds a Master of Science degree in Electro-Mechanical Engineering, a Master degree in Applied Economics and Business Degree from INSEAD, France. Peter Janssen was born in 1966.
Peter started his career as an assistant Professor at the University of Leuven in Belgium, was a reserve officer at the Belgian Air Force and worked in the semiconductor division of Air Products in Pennsylvania, US. He holds a Master of Science degree in Electro-Mechanical Engineering, a Master degree in Applied Economics and Business Degree from INSEAD, France. Peter Janssen was born in 1966.
Martin Möller
Chief Financial Officer
IR contact
Dr. Monika Bauman (Buttkereit)
Head of Investor Relations Biotest AG
Landsteinerstraße 5
D-63303 Dreieich
Phone: +49 (0) 61 03 – 801 4406
Fax: +49 (0) 61 03 – 801 347
E-Mail: ir@biotest.com